SynthesisJournal of medical virology2025
Systematic Review of Postvaccination Ocular Adverse Events: A Comprehensive Analysis of Published Reports.
Synthesis in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Postvaccination Ocular Adverse Events: A Comprehensive Analysis of Published Reports.Journal of medical virology · 2025Pooled it
- Multifocal mucocutaneous herpes simplex virus type 1 infection temporally associated with seasonal influenza vaccination in a young adult without a known immunocompromising condition: A case report.Human vaccines & immunotherapeutics · 2026Article
- Vaccine-Associated Anterior Uveitis.Vaccines · 2026Review
- Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ocular adverse events following COVID-19 vaccination are well described; however, systematic analyses of non-COVID antiviral vaccines remain limited. This review aimed to evaluate ocular complications associated with non-COVID antiviral immunizations, including influenza, varicella-zoster (VZV), human papillomavirus (HPV), and hepatitis B (HBV) vaccines. A systematic search (PROSPERO CRD4202450873) identified 122 patients (184 eyes) from 8,487 publications, including case reports, case series, and observational studies. Uveitis was the most common (92/184 eyes; 50.0%, 95% CI 42.8%-57.2%), frequently following influenza vaccination (35/122; 28.7%, 95% CI 20.7%-36.7%). Most patients (95/122; 77.9%, 95% CI 70.5%-85.3%) required systemic corticosteroids, reflecting predominant inflammation. Ocular symptoms occurred within 30 days in 84.4% (103/122)of cases, with peak onset at 7-30 days (62/122; 50.8%, 95% CI 42.0%-59.6%). Despite appropriate treatment, 18 patients (20.0%, 95% CI 13.0%-29.4%) experienced persistent inflammation or required therapy beyond 1 month, categorized as "long-vax", defined as ocular symptoms persisting for ≥ 4 weeks after vaccination. Although rare, antiviral vaccine-associated ocular complications may persist, posing a risk of long-term visual morbidity and emphasizing the importance of clinician awareness, postvaccination surveillance, and counseling for patients receiving repeated or combined vaccine exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.